Incorporating Genetic Testing Into the Care of Patients With Amyotrophic Lateral Sclerosis/Frontotemporal Degeneration Spectrum Disorders.
Journal
Neurology. Clinical practice
ISSN: 2163-0402
Titre abrégé: Neurol Clin Pract
Pays: United States
ID NLM: 101577149
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
13
03
2023
accepted:
14
08
2023
pmc-release:
01
10
2024
medline:
22
9
2023
pubmed:
22
9
2023
entrez:
22
9
2023
Statut:
ppublish
Résumé
Amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) spectrum disorders have a strong genetic component. Genetic counselors are a limited resource, and therefore, other providers must be prepared to integrate genetic testing into their practice. Recent ALS/FTD studies have demonstrated that lack of family history does not preclude a genetic etiology. The benefits of a genetic diagnosis have expanded to include the potential to treat; thus, genetic testing is increasingly recommended to be offered to all persons with ALS/FTD. Offering genetic testing to persons with ALS/FTD spectrum disorders should be part of routine clinical neurologic care. All genetic testing should include discussion about the medical and psychosocial implications of testing for the patient and family members. Neurologists should be prepared to facilitate this process and recognize when referral to a genetic counselor is indicated.
Identifiants
pubmed: 37736067
doi: 10.1212/CPJ.0000000000200201
pii: CPJ-2023-000125
pmc: PMC10511270
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e200201Informations de copyright
© 2023 American Academy of Neurology.
Déclaration de conflit d'intérêts
L. Dratch has consulted for Passage Bio, Biogen, and Sano Genetics. All other authors report no disclosures relevant to the manuscript. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.FIVE NEW THINGSNeurologists should incorporate discussions of genetic testing into the care of patients with ALS/FTD spectrum disorders.Genetic testing should be offered to all patients with ALS/FTD spectrum disorders because of management and psychosocial implications, clinical trials eligibility, emerging gene-based treatments, and determination of recurrence risks for family members.When offering genetic testing, the clinician should discuss the impact of testing for the patient and their relatives, timing of test ordering and results disclosure, review of different testing options and their limitations, and overview of possible test results.Careful consideration must be given to the genetic testing being ordered and interpretation of results. Specific attention should be paid to which genes are included in the analysis and what sequencing technology is used.In diagnostic genetic testing, referral to a genetic counselor should be prioritized for those requiring (1) additional conversation regarding decision-making about testing, (2) assistance with interpretation of genetic test results (e.g., uncertain findings), (3) guidance for further genetic evaluation if initial testing is not diagnostic, and (4) additional counseling to address emotional implications or strategies to communicate with family members. Referral to a genetic counselor should be made for all asymptomatic individuals considering predictive genetic testing.
Références
Neurology. 2016 Jun 14;86(24):2295-302
pubmed: 27194384
Clin Lab Med. 2020 Sep;40(3):271-287
pubmed: 32718499
Brain. 2022 May 24;145(4):1207-1210
pubmed: 35020823
J Genet Couns. 2020 Oct;29(5):718-727
pubmed: 31856388
J Genet Couns. 2013 Aug;22(4):437-47
pubmed: 23292684
J Neurol. 2022 Feb;269(2):676-692
pubmed: 33649871
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Neurol Genet. 2019 Jan 07;5(1):e301
pubmed: 30697590
PEC Innov. 2022 Nov 24;2:100108
pubmed: 37214502
Neurol Clin. 2017 May;35(2):339-374
pubmed: 28410663
Genes (Basel). 2021 Dec 28;13(1):
pubmed: 35052416
Amyotroph Lateral Scler Frontotemporal Degener. 2022 Nov;23(7-8):562-574
pubmed: 35343344
N Engl J Med. 2022 Sep 22;387(12):1099-1110
pubmed: 36129998
Amyotroph Lateral Scler Frontotemporal Degener. 2019 May;20(3-4):216-221
pubmed: 30931630
Genet Med. 2022 Jul;24(7):1407-1414
pubmed: 35802134
Eur J Hum Genet. 2019 Nov;27(11):1630-1638
pubmed: 31189929
Neurology. 2017 Mar 7;88(10):991-999
pubmed: 28159885
Handb Clin Neurol. 2018;147:23-36
pubmed: 29325614
J Neurol Neurosurg Psychiatry. 2017 Dec;88(12):1042-1044
pubmed: 28642287